2019 · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · paywalled
A patient-centric liquid chromatography-tandem mass spectrometry microsampling assay for analysis of cannabinoids in human whole blood: Application to pediatric pharmacokinetic study
Moorthy et al.
The finding, in our words
The authors developed and validated an LC-MS/MS assay for THC, CBD and CBN from 20 µL VAMS blood samples with linear calibration curves and inter-day accuracies of 94.4 to 107 per cent, then applied it to a pediatric pharmacokinetic study, demonstrating that patient-centric microsampling can support decentralised therapeutic drug monitoring of cannabinoids in children.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This study employed volumetric absorptive microsampling to collect blood samples from neonates, revealing that existing propofol pharmacokinetic models poorly predicted drug levels in this population. A newly developed meta-model provided accurate predictions, validating the use of patient-centric microsampling for therapeutic drug monitoring in preterm and term infants.
Rantanen et al., European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (paywalled) · source ↗
The study validated an LC-MS/MS method for eight antiepileptic drugs and two metabolites in dried blood spot and VAMS formats, with satisfactory analytical performance and stability, and was the first to include the oxcarbazepine metabolite DHCB. In 80 paired patient samples, microsampling concentrations showed promising correlation with plasma, supporting decentralised therapeutic drug monitoring of antiepileptic treatment.
Cobo-Golpe et al., Journal of analytical toxicology · source ↗
The study developed and validated a rapid LC-MS/MS method for quantifying cefazolin in capillary whole blood collected via VAMS, plasma, and plasma ultrafiltrate, showing robust performance across matrices and successful application in a pediatric pilot cohort for therapeutic drug monitoring.
Kocur et al., Clinica chimica acta; international journal of clinical chemistry (paywalled) · source ↗
Dried saliva collected with the Mitra device correlated strongly with wet saliva but poorly with plasma unbound and total concentrations, indicating it is not a reliable substitute for plasma in routine therapeutic drug monitoring of mycophenolic acid and its glucuronide metabolite. Capillary blood collected via VAMS remains a promising alternative for long term monitoring in paediatric patients.
This study validated a method for quantifying fluconazole using the Mitra device, demonstrating sufficient accuracy and precision for therapeutic drug monitoring in paediatric patients.